ESL Biosciences, in partnership with Euroimmun AG, offer the most comprehensive range of diagnostic products and services for the determination of autoantibodies
Idiopathic inflammatory myopathies (IIM) are rare autoimmune diseases of skeletal muscle. Differentiation and correct diagnosis of myopathy subtypes are challenging due to rarity of the diseases, the varying clinical presentation and the possibility of overlap syndromes. Comprehensive multiparametric testing is essential to maximize the diagnostic information obtained from the analysis.
New Autoimmune Myopathies Profile 7 Lineblot 16 Myositis Antigens Plus cN-1A
The new EUROLine Autoimmune Myopathies Profile 7 combines the 16 antigens from the Myopathies Profile 4 with cN-1A.
cN-1A - The first serological marker for Inclusion Body Myositis (IBM)
- Anti-cN-1A autoantibodies are found in 33-76% IBM patients
- Specificity for IBM is between 87-100%
Due to the high specificity of Anti-cN-1A antibodies, their detection can in particular aid the differentiation of IBM from other muscle diseases including PM, DM, necrotising myopathy, muscular dystrophy or myasthenia gravis.
Autoimmune Myopathies Profile 7 Offers:
- Detection of 17 myositis autoantibodies in one test
- Early and reliable diagnosis of IBM with the biomarker cN-1A
- Differentiation between PM, DM, IBM and Overlap Syndromes
- Increase in overall diagnostic sensitivity for autoimmune myopathies
- Reduction in the number of muscle biopsies
-Same incubation scheme as Autoimmune Myopatheis Profile 3 and 4
-Automation available with EUROBlot One and EUROBlot Master
Contact ESL Representatives for More Information on EUROIMMUN Autoimmune Myopathies Diagnostic Range
